ENZ - Enzo Biochem Inc Stock Price, Fair Value and News

$0.73-0.01 (-1.35%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

ENZ Price Action

Last 7 days

4.3%

Last 30 days

-24.7%

Last 90 days

-34.8%

Trailing 12 Months

-47.9%

ENZ RSI Chart

ENZ Valuation

Market Cap

38.1M

Price/Earnings (Trailing)

-1.67

Price/Sales (Trailing)

1.26

EV/EBITDA

2.05

Price/Free Cashflow

-1.74

ENZ Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ENZ Fundamentals

ENZ Revenue

Revenue (TTM)

30.3M

Rev. Growth (Yr)

-20.41%

Rev. Growth (Qtr)

-17.45%

ENZ Earnings

Earnings (TTM)

-22.8M

Earnings Growth (Yr)

48.97%

Earnings Growth (Qtr)

74.77%

ENZ Profitability

Operating Margin

45.22%

EBT Margin

-23.79%

Return on Equity

-47.92%

Return on Assets

-30.33%

Free Cashflow Yield

-57.36%

ENZ Investor Care

Shares Dilution (1Y)

3.47%

Diluted EPS (TTM)

-0.45

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	32.8M	33.3M	31.9M	30.3M
2023	31.9M	31.5M	31.1M	31.8M
2022	118.2M	111.6M	32.6M	32.2M
2021	96.6M	112.4M	117.7M	115.6M
2020	78.6M	77.3M	76.0M	84.5M
2019	88.6M	83.0M	81.2M	79.9M
2018	103.1M	102.1M	101.0M	95.4M
2017	105.6M	106.2M	105.2M	104.1M
2016	99.4M	101.9M	102.8M	103.9M
2015	96.8M	96.8M	97.6M	98.0M
2014	92.9M	94.3M	95.9M	96.6M
2013	100.2M	96.8M	93.7M	92.2M
2012	103.4M	103.5M	103.1M	103.0M
2011	99.6M	100.8M	102.0M	102.1M
2010	0	0	97.1M	98.3M

Get all data in R, Python etc through our Historical Stock Data APIs

About Enzo Biochem Inc

Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing Ãƒâ€šÃ¢â‚¬ËœSTAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in Farmingdale, New York.

CEO	Ms. Kara Cannon
WEBSITE	enzo.com
SECTOR	Healthcare
INDUSTRY	Diagnostics & Research
EMPLOYEES	465

Enzo Biochem Inc Frequently Asked Questions

What is the ticker symbol for Enzo Biochem Inc? What does ENZ stand for in stocks?

ENZ is the stock ticker symbol of Enzo Biochem Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Enzo Biochem Inc (ENZ)?

As of Tue Dec 24 2024, market cap of Enzo Biochem Inc is 38.14 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ENZ stock?

You can check ENZ's fair value in chart for subscribers.

Is Enzo Biochem Inc a good stock to buy?

The fair value guage provides a quick view whether ENZ is over valued or under valued. Whether Enzo Biochem Inc is cheap or expensive depends on the assumptions which impact Enzo Biochem Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ENZ.

What is Enzo Biochem Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Dec 24 2024, ENZ's PE ratio (Price to Earnings) is -1.67 and Price to Sales (PS) ratio is 1.26. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ENZ PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Enzo Biochem Inc's stock?

In the past 10 years, Enzo Biochem Inc has provided -0.168 (multiply by 100 for percentage) rate of return.